1 active not recruiting, 1 not yet recruiting, 1 recruiting. 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow TQB2102 Injection: new trials by email Literature Review of TQB2102 Injection trials Research Report on TQB2102 Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets - HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 142 | 2026-03-01 | 2026-03-19 |
| Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer TQB2102 Injection, Trastuzumab Emtansine for Injection - Metastatic Breast Cancer | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 246 | 2025-07-07 | 2025-08-14 |
| Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers TQB2102 injection - Advanced Cancer | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 219 | 2023-03-09 | 2025-08-01 |
Breast Neoplasms (1)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (3)
China (3)